Ariana K. von Lersner

Ariana K. von Lersner

Auto-generated profile, based on publicly available information

Ariana K. von Lersner

Division of Hematology & Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2024 in ACS Nano
Verified
Journal Article
Open access
ALAriana K. von Lersner
Ariana K. von Lersner
FFFabiane Fernandes
Fabiane Fernandes
POPatricia Midori Murobushi Ozawa
Patricia Midori Murobushi Ozawa
MJMarques Jackson
Marques Jackson
MMMatthieu Masureel
Matthieu Masureel
AZAndries Zijlstra
Andries Zijlstra
Mammalian cells release a heterogeneous array of extracellular vesicles (EVs) that contribute to intercellular communication by means of the cargo that they carry. To resolve EV heterogeneity and determine if cargo is partitioned into select EV populations, we developed a method named "EV Fingerprinting" that discerns distinct vesicle populations using dimensional reduction of multiparametric data collected by quantitative single-EV flow cytometry. EV populations were found to be discernible by a combination of membrane order and EV size, both of which were obtained through multiparametric analysis of fluorescent features from the lipophilic dye Di-8-ANEPPS incorporated into the lipid bilayer. Molecular perturbation of EV secretion and biogenesis through respective ablation of the small GTPase Rab27a and overexpression of the EV-associated tetraspanin CD63 revealed distinct and selective alterations in EV populations, as well as cargo distribution. While Rab27a disproportionately affects all small EV populations with high membrane order, the overexpression of CD63 selectively increased the production of one small EV population of intermediate membrane order. Multiplexing experiments subsequently revealed that EV cargos have a distinct, nonrandom distribution with CD63 and CD81 selectively partitioning into smaller vs larger EVs, respectively. These studies not only present a method to probe EV biogenesis but also reveal how the selective partitioning of cargo contributes to EV heterogeneity.

18 February 2019 in Clinical & Experimental Metastasis
Verified
Journal Article
Closed access
PDF file
ALAriana von Lersner
Ariana von Lersner
LDLenny Droesen
Lenny Droesen
AZAndries Zijlstra
Andries Zijlstra

1 October 2018 in Neoplasia
Verified
Journal Article
Open access
SMSelma Maacha
Selma Maacha
JHJun Hong
Jun Hong
ALAriana von Lersner
Ariana von Lersner
AZAndries Zijlstra
Andries Zijlstra
ABAbbes Belkhiri
Abbes Belkhiri
Esophageal adenocarcinoma (EAC) is a highly aggressive malignancy that is characterized by resistance to chemotherapy and a poor clinical outcome. The overexpression of the receptor tyrosine kinase AXL is frequently associated with unfavorable prognosis in EAC. Although it is well documented that AXL mediates cancer cell invasion as a downstream effector of epithelial-to-mesenchymal transition, the precise molecular mechanism underlying this process is not completely understood. Herein, we demonstrate for the first time that AXL mediates cell invasion through the regulation of lysosomes peripheral distribution and cathepsin B secretion in EAC cell lines. Furthermore, we show that AXL-dependent peripheral distribution of lysosomes and cell invasion are mediated by extracellular acidification, which is potentiated by AXL-induced secretion of lactate through AKT-NF-κB-dependent MCT-1 regulation. Our novel mechanistic findings support future clinical studies to evaluate the therapeutic potential of the AXL inhibitor R428 (BGB324) in highly invasive EAC.

16 February 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KHKatie E Hebron
Katie E Hebron
ELElizabeth Y. Li
Elizabeth Y. Li
SEShanna A. Arnold Egloff
Shanna A. Arnold Egloff
ALAriana K. von Lersner
Ariana K. von Lersner
CTChase Taylor
Chase Taylor
AZAndries Zijlstra
Andries Zijlstra
While many adhesion receptors are known to influence tumor progression, the mechanisms by which they dynamically regulate cell-cell adhesion remain elusive. We previously identified Activated Leukocyte Cell Adhesion Molecule (ALCAM) as a clinically relevant driver of metastasis and hypothesized that a tunable mechanism of ectodomain shedding regulates its contribution to dissemination. To test this hypothesis, we examined an under-explored ALCAM splice variant (ALCAM-Iso2) and demonstrated that loss of the membrane-proximal region of ALCAM (exon 13) increased metastasis four-fold. Mechanistic studies identified a novel MMP14-dependent membrane distal cleavage site in ALCAM-Iso2, which mediated a ten-fold increase in shedding, thereby decreasing cellular cohesion. Importantly, the loss of cohesion is not limited to the cell capable of shedding because the released extracellular domain diminished cohesion of non-shedding cells through disruption of ALCAM-ALCAM interactions. ALCAM-Iso2-dominated expression in bladder cancer tissue, compared to normal bladder, further emphasizes that ALCAM alternative splicing may contribute to clinical disease progression. The requirement for both the loss of exon 13 and the gain of metalloprotease activity suggests that ALCAM shedding and concomitant regulation of tumor cell adhesion is a locally tunable process.

11 November 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
ALAriana K. von Lersner
Ariana K. von Lersner
FFFabiane C. L. Fernandes
Fabiane C. L. Fernandes
POPatricia M. M. Ozawa
Patricia M. M. Ozawa
SLSierra M. Lima
Sierra M. Lima
TVTatyana Vagner
Tatyana Vagner
AZAndries Zijlstra
Andries Zijlstra
Mammalian cells release a heterogeneous array of extracellular vesicles (EVs) that impact human biology by contributing to intercellular communication. To resolve EV heterogeneity and define the EV populations associated with specific biological processes, we developed a method named “EV Fingerprinting” that discerns distinct vesicle populations using dimensional reduction of multi-parametric data collected by quantitative single-EV flow cytometry. After validating this method against synthetic standards, the EV Fingerprinting analysis of highly purified EVs enabled a much more granular resolution of biochemically distinct EV populations than previously established methods. The analysis of EVs produced after molecular perturbation of EV biogenesis through ablation of the GTPase Rab27a and overexpression of the tetraspanin CD63 revealed that EV Fingerprinting reflects the molecular state of a cell. Subsequent analysis of human plasma demonstrates the capacity of EV Fingerprinting to resolve EV populations in complex biological samples and detect tumor-cell derived EVs.

1 July 2026 in JCO Oncology Advances
Verified
Journal Article
Open access
AMAllison D. Morris
Allison D. Morris
SKSamantha R. Keller
Samantha R. Keller
RFRachel A. Francis
Rachel A. Francis
ALAriana von Lersner
Ariana von Lersner
ZFZoe Finer
Zoe Finer
AHAndreana Holowatyj
Andreana Holowatyj
PURPOSE: Reproductive care—including discussions about cancer-related infertility risk—is part of the recommended standard of care for all patients with cancer. Despite rising cancer incidence among adults younger than 50 years (early-onset), the evaluation of patients' knowledge about cancer-related infertility risk is limited. We characterized factors associated with lack of awareness of potential cancer-related infertility risk as reported by patients with early-onset cancer. PATIENTS AND METHODS: Using data from the Reproductive Health After Cancer Diagnosis and Treatment (REACT) Study, we identified individuals diagnosed with a first primary early-onset cancer between 2006 and 2021. Awareness of potential cancer-related infertility risk was determined using questionnaires. Logistic regression models were fitted to examine associations between a lack of awareness of cancer-related infertility risk and patient-level factors. RESULTS: Among 636 patients, 28.9% (n = 184) reported never being told that their cancer treatments may affect their fertility. Patients who were aware of a potential cancer-related infertility risk had heard this information, on average, from two unique sources (mean = 2.2, std = 1.3)—with 90.1% of all sources derived from clinical interactions/settings. Patients who self-identified with a racial ethnic minority (REM) population—inclusive of African American/Black, American Indian, Asian, Hispanic/Spanish/Latino/a/x, Middle Eastern or North African, or multiple races—were nearly twice as likely to report an unawareness of infertility risk compared with patients who identified as non-Hispanic White after adjusting for diagnosis age and year, sex, insurance coverage, marital status, and pregnancy history (odds ratio, 1.70 [95% CI, 1.05 to 2.74]; P = .03). CONCLUSION: Three in every 10 patients with early-onset cancer reported never having been told that cancer treatments may affect their fertility. Individual factors contributed to differences in patients' knowledge of potential cancer-related infertility risk. Further study is needed to address this care gap among patients and providers to deliver concordant, high-quality reproductive and oncology care to this growing population.